Financial Data and Key Metrics Changes - Amphastar Pharmaceuticals reported a year-over-year increase in net revenue to $171.8 million, representing a substantial increase of 23% compared to the same period last year [6][12] - Net income increased over 66% to $43.2 million or $0.81 per share, up from $26 million or $0.50 per share in the first quarter of 2023 [17] - Adjusted net income rose to $55.3 million or $1.04 per share compared to $32.1 million or $0.62 per share in the previous year [17] Business Line Data and Key Metrics Changes - Glucagon injection sales increased 11% to $28.5 million from $25.7 million, benefiting from the first full quarter of sales in Canada [12] - BAQSIMI revenues reached $38.4 million, up 22% from $31.4 million in the first quarter of 2023, with net revenues from direct shipments at $13.8 million and $24.6 million from Lilly under the TSA agreement [14] - Sales of epinephrine and phytonadione increased by 30% and 29%, respectively, due to supplier shortages, with epinephrine sales rising to $26.1 million from $20.1 million [13] Market Data and Key Metrics Changes - The company noted a consistent demand trend for hospital products, which is expected to remain robust throughout the year [7] - The transition of BAQSIMI into the U.S. market has been successful, with initial stocking contributing to sales growth [8] - The mix of glucagon injection usage is approximately one-third for antihypoglycemic purposes and two-thirds for diagnostics [24] Company Strategy and Development Direction - Amphastar is focused on expanding its product portfolio, with plans to launch 4 to 5 new products this year, including REXTOVY, an intranasal naloxone product [9] - The company is prioritizing investments in sales and marketing for BAQSIMI to enhance its market presence [9] - The management emphasized the importance of adapting to market fluctuations and maintaining a diverse portfolio for sustained success [11] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about growth prospects, particularly with BAQSIMI and upcoming product launches [11] - The company is cautiously optimistic regarding the FDA's review process for AMP-002, indicating positive ongoing dialogue with the agency [21] - Management acknowledged the challenges posed by pricing dynamics and competition in the glucagon market, particularly with Gvoke [20] Other Important Information - Research and development expenditures decreased by 14% to $17 million due to the timing of clinical trials [17] - Selling, distribution, and marketing expenses increased by 32% to $9.4 million, reflecting the expansion of the salesforce and marketing efforts for BAQSIMI [16] Q&A Session Summary Question: Feedback on BAQSIMI and pricing implications - Management indicated that contracts with payers are aligning with previous pricing set by Lilly, but higher fees to wholesalers are expected to lead to low single-digit pricing declines [20] Question: Update on AMP-002 interactions with the FDA - Management confirmed that there have been no new requests from the FDA and expressed cautious optimism about moving the application forward [21] Question: BAQSIMI sales force and manufacturing plans - The company is currently using an outside sales force for BAQSIMI and is monitoring the need to bring it in-house, while in-house manufacturing is deemed complex and unlikely in the near term [23][24] Question: Future growth expectations for epinephrine sales - Management noted that while current sales are strong, maintaining such growth levels may be challenging due to production capacity limits [32] Question: Impact of product mix on growth and patient inventory - The shelf life of products is generally around two years, and the transition from single-use kits to brands offering multiple units may affect patient inventory management [35] Question: Market opportunity for AMP-004 and patent challenges - Management highlighted the significant market opportunity for AMP-004, estimating it to be over $4 billion, and discussed ongoing discussions regarding patent listings with the FTC [40][41]

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 35.06%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $0.87 per share when it actually produced earnings of $0.88, delivering a surprise of 1.15%.Over th ...

EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024 Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA – May 8, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2024. First Quarter Highlights ● Net revenues of $171.8 million for the first quarter ● GAAP net income of $43.2 million, or $0.81 per share, for the ...

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Amphastar Pharmaceuticals, with a focus on how actual results compare to estimates impacting stock price [1] Group 1: Earnings Expectations - Amphastar is expected to report quarterly earnings of $0.77 per share, reflecting a year-over-year increase of +24.2% [2] - Revenues are projected to be $171.6 million, which is a 22.6% increase from the same quarter last year [2] Group 2: Estimate Revisions - The consensus EPS estimate has been revised 3.48% lower in the last 30 days, indicating a reassessment by analysts [2] - The direction of estimate revisions may not always reflect in the aggregate change [2] Group 3: Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Amphastar is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.68% [5] - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [4] Group 4: Historical Performance - Amphastar has consistently beaten consensus EPS estimates, achieving a surprise of +1.15% in the last reported quarter [7] - The company has surpassed consensus EPS estimates in all of the last four quarters [7] Group 5: Investment Considerations - While an earnings beat may not solely dictate stock movement, betting on stocks expected to exceed earnings expectations can enhance success odds [8] - Amphastar is viewed as a compelling candidate for an earnings beat, but investors should consider other influencing factors [8]

Group 1 - Amphastar Pharmaceuticals (AMPH) has a strong history of beating earnings estimates, particularly in the last two quarters with an average surprise of 32.72% [1] - In the last reported quarter, Amphastar achieved earnings of $0.88 per share, surpassing the Zacks Consensus Estimate of $0.87 per share by 1.15% [1] - The previous quarter saw Amphastar exceed expectations significantly, reporting earnings of $1.15 per share against an estimate of $0.70 per share, resulting in a surprise of 64.29% [1] Group 2 - Earnings estimates for Amphastar have been trending higher, supported by its history of earnings surprises [2] - The stock has a positive Zacks Earnings ESP of +0.95%, indicating bullish sentiment among analysts regarding its near-term earnings potential [3] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing nearly 70% success in such cases [2][3] Group 3 - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [3] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [3] - It is crucial for investors to check a company's Earnings ESP before quarterly releases to enhance the chances of successful investment decisions [4]

Core Viewpoint - Three stocks have been added to the Zacks Rank 5 (Strong Sell) List due to downward revisions in earnings estimates over the last 60 days [1] Company Summaries - **Amphastar Pharmaceuticals, Inc. (AMPH)**: A bio-pharmaceutical company with a current year earnings estimate revised downward by 4.1% [1] - **BayCom Corp (BCML)**: The bank holding company for United Business Bank, with a current year earnings estimate revised downward by 12.4% [1] - **Diversified Healthcare Trust (DHC)**: Owns medical office and life science properties, senior living communities, and wellness centers, with a current year earnings estimate revised downward by 16.7% [1]

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Amphastar Pharmaceuticals (AMPH) .Amphastar currently has an average broke ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2023 Earnings Conference Call February 28, 2024 5:00 AM ET Company Participants Dan Dischner - SVP of Corporate Communications William Peters - CFO Tony Marrs - Executive Vice President of Regulatory Affairs and Clinical Operations Conference Call Participants Timothy Chiang - Capital One David Amsellem - Piper Sandler Glen Santangelo - Jefferies Operator Greetings, and welcome to the Amphastar Pharmaceuticals fourth quarter earnings call. [Operator Instructi ...

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.15%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $0.70 per share when it actually produced earnings of $1.15, delivering a surprise of 64.29%.Over th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number 001-36509 AMPHASTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | --- | |-------| | | | | | | | | | | | ...